Clinical Trial: A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase 2, Randomized, Double-blind-placebo-controlled and Open-label-Sevelamer Hydrochloride-controlled, Dose-ranging Study for ASP1585 in Patients With Chronic Kidney Disease(CKD) and Same as current
Current Secondary Outcome:
- Change in serum phosphorus level by time [ Time Frame: Up to 4 weeks ]
- Percent of patients meeting the target range of serum phosphorus (3.5-6.0 mg/dL) and achieving time [ Time Frame: 4 Weeks ]
- Change in corrected serum Ca level [ Time Frame: 4 weeks ]
- Change in Ca×P [ Time Frame: 4 weeks ]
- Change in intact PTH [ Time Frame: 4 weeks ]
Original Secondary Outcome: Change in serum phosphorus level by time Percent of patients meeting the target range of serum phosphorus (3.5-6.0 mg/dL) and achieving time Change in corrected serum Ca level Change in Ca×P Change in intact PTH [ Time Frame: 4 Weeks ]
Information By: Astellas Pharma Inc
Dates:
Date Received: July 18, 2007
Date Started: October 2007
Date Completion:
Last Updated: March 21, 2011
Last Verified: March 2011
